购物车
您的购物车当前为空
KRASG12C IN-15 (Compound 21) 是一种可口服的KRASG12C抑制剂,能够以19 nM的IC50抑制由SOS1介导的GDP/GTP交换。它还可通过抑制ERK磷酸化表现出作用,IC50为0.051 μM,并抑制KRASG12C突变的MIA PaCa-2细胞活力,IC50为0.023 μM。在MIA PaCa-2异种移植小鼠模型中,KRASG12C IN-15 显示出抗肿瘤活性。

KRASG12C IN-15 (Compound 21) 是一种可口服的KRASG12C抑制剂,能够以19 nM的IC50抑制由SOS1介导的GDP/GTP交换。它还可通过抑制ERK磷酸化表现出作用,IC50为0.051 μM,并抑制KRASG12C突变的MIA PaCa-2细胞活力,IC50为0.023 μM。在MIA PaCa-2异种移植小鼠模型中,KRASG12C IN-15 显示出抗肿瘤活性。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 10-14周 | |
| 50 mg | 待询 | 10-14周 |
| 产品描述 | KRASG12C IN-15 (Compound 21) is an orally active KRASG12C inhibitor that effectively blocks SOS1-mediated GDP/GTP exchange with an IC50 of 19 nM. It inhibits ERK phosphorylation with an IC50 of 0.051 μM and reduces the viability of KRASG12C mutant MIA PaCa-2 cells with an IC50 of 0.023 μM. Additionally, KRASG12C IN-15 demonstrates antitumor activity in a MIA PaCa-2 xenograft mouse model. |
| 分子量 | 497.603 |
| 分子式 | C31H32FN3O2 |
| CAS No. | 2768868-14-8 |
| Smiles | FC=1C(=C2C([C@]3(C(C)(C)[C@@](C2)(C3)[H])[H])=NC1N4CC5(CC4)CN(C(C=C)=O)C5)C=6C7=C(C=C(O)C6)C=CC=C7 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
对于不同动物的给药剂量换算,您也可以参考 更多